DIGITALX LIMITED — Director's Dealing 2018

Jul 1, 2018

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	DigitalX Limited
ABN	59 009 575 035

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Irwin Rubinstein
Date of last notice	1 December 2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Irwin Biotech Nominees Pty Ltd ATF BIOA Trust. Peter Irwin Rubinstein is the sole director and shareholder of Irwin Biotech Nominees Pty Ltd and a beneficiary of BIOA Trust.
Date of change	26 June 2018 – 29 June 2018

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	Direct 617,284 Subscription Options exercisable at $0.0324 each on or before 1 September 2020 Indirect 5,680,000 Fully Paid Ordinary Shares1 3,000,000 Fully Paid Ordinary Shares2 7,000,000 Fully Paid Ordinary Shares3 17 Convertible Notes with a face value of $10,000 each, converting to fully paid ordinary Shares at $0.027 per Share (6,296,296 Shares) and maturing on 14 September 20181 1. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust. 2. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund. 3. Held by ValueAdmin.Com Pty Ltd.
Class	Fully Paid Ordinary Shares
Number acquired	1,500,000 Fully Paid Ordinary Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Average price of $0.084 per Share

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change

Direct 617,284 Subscription Options exercisable at $0.0324 each on or before 1 September 2020 Indirect 7,180,000 Fully Paid Ordinary Shares1 3,000,000 Fully Paid Ordinary Shares2 7,000,000 Fully Paid Ordinary Shares3 17 Convertible Notes with a face value of $10,000 each, converting to fully paid ordinary Shares at $0.027 per Share (6,296,296 Shares) and maturing on 14 September 20181 1. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust. 2. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund. 3. Held by ValueAdmin.Com Pty Ltd.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

On Market Purchase

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 4

01/01/2011